更汀蘆單抗
化合物
更汀蘆單抗（INN：Gantenerumab）是由羅氏製藥公司開發的一種用於治療阿爾茨海默病的單株抗體。[1][2]
_5CSZ.png) | |
| 單株抗體 | |
|---|---|
| 種類 | 完整抗體 |
| 目標 | β澱粉樣蛋白（Aβ40/42） |
| 臨床資料 | |
| ATC碼 |
|
| 法律規範狀態 | |
| 法律規範 |
|
| 識別資訊 | |
| CAS號 | 1043556-46-2  |
| ChemSpider |
|
| UNII | |
| KEGG | |
| 化學資訊 | |
| 化學式 | C6496H10072N1740O2024S42 |
| 摩爾質量 | 146.3 kg/mol (peptide) |
更汀蘆單抗的III期臨床試驗因缺乏療效而提前停止。[4]更汀蘆單抗也在患有阿爾茨海默病高風險的年輕患者中進行了評估，[5]但經過五年的治療，該藥物對減緩患者認知能力下降幾乎沒有作用。[6]
參考資料
編輯- ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Gantenerumab (PDF). American Medical Association. [2023-12-06]. （原始內容存檔 (PDF)於2012-02-20）.
- ^ International Nonproprietary Names for Pharmaceutical Substances (INN) (PDF). World Health Organization. （原始內容 (PDF)存檔於2012-02-11）.
- ^ Panza F, Seripa D, Lozupone M, Solfrizzi V, Imbimbo BP, Barulli MR, et al. The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset. Expert Opinion on Biological Therapy. January 2018, 18 (1): 25–35. PMID 29037101. S2CID 4795458. doi:10.1080/14712598.2018.1389885.
- ^ Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease. Alzheimer's Research & Therapy. December 2017, 9 (1): 95. PMC 5723032
. PMID 29221491. doi:10.1186/s13195-017-0318-y .
- ^ Clinical trial number NCT01760005 for "Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. (DIAN-TU)" at ClinicalTrials.gov
- ^ Kolata G. An Alzheimer's Treatment Fails: 'We Don't Have Anything Now'. The New York Times. 10 February 2020 [2023-12-06]. （原始內容存檔於2023-12-07）.
 | 這是一篇作用於神經系統的藥品小作品。您可以透過編輯或修訂擴充其內容。 |